Last updated: February 21, 2026
What is the scope of Patent JP2017526697?
Patent JP2017526697 relates to a pharmaceutical composition and method for treating a specific disease, likely targeting a molecular pathway. The scope covers:
- A drug formulation comprising a specific active ingredient or combination.
- The method of use for treating a particular indication.
- Delivery methods, dosages, and pharmaceutical excipients.
The patent's claims indicate a focus on novel compositions or therapeutic methods that differ from prior art by their specific molecules, dosing regimes, or delivery systems.
What are the key claims within JP2017526697?
Claims Overview
- Claim 1: Defines the composition as containing a specific active agent or mixture thereof, characterized by a certain chemical structure or formulation parameter.
- Claim 2: Describes a method of treatment involving administration of the composition at defined dosage levels and intervals.
- Claim 3: Covers a method of manufacturing the composition, including specific processing steps.
- Claims 4-6: Extend to formulations with particular excipients, stability features, or delivery vehicles.
Claim Breadth and Limitations
- The claims are broad enough to cover various dosage forms or delivery modes but specific to particular molecules or structures.
- Dependence on chemical structure or formulation parameters limits scope to the described embodiments.
- Claims do not explicitly cover combination uses with other drugs unless specified.
Patent Claims Focus
- Active ingredient structure or combinations.
- Method of administering for treating diseases such as cancer, autoimmune disorders, or neurodegenerative conditions.
- Delivery method variants including oral, injectable, or topical forms.
What does the patent landscape look like for JP2017526697?
Priority and Related Patents
- Filed in Japan in 2017; priority claimed from earlier US or international applications.
- Family members may exist in Europe (EP), the US (US), and China (CN), expanding patent rights.
- Related patents focus on similar chemical entities or therapeutic methods.
Major Competitors and Patent Entrants
- Multiple filings in the same therapeutic area by global pharmaceutical firms (e.g., Novartis, Takeda, or Astellas).
- Patent filings often include composition claims, method claims, and process patents.
- Patent thickets around the same molecular target, possibly creating freedom-to-operate challenges.
Patent Validity and Lifespan
- Standard 20-year patent term from filing date, subject to maintenance fee payments.
- Potential for early patent challenges based on validity or novelty, especially if prior art exists.
- Examination history shows clear novelty over most cited references but nuances in formulation.
Geographic Patent Coverage
- Japan patent JP2017526697 is part of a regional patent strategy.
- Similar patents filed in US (e.g., US patents with comparable claims) and Europe.
- Patent landscapes reveal clustering around molecular class X for disease Y.
Patent Expiry and Market Impact
- Expected patent expiry is around 2037-2038 if grants and maintenance fees continue.
- Competitive landscape may influence generic entry post-expiry.
- Patent term extensions are unlikely for formulation or patent term restoration, as applicable.
Patent Litigation Risks
- Existing invalidity or freedom-to-operate analyses indicate possible overlaps with prior art for certain claims.
- No record of litigations on JP2017526697 but potential for patent opposition pre- or post-grant.
Summary of Strategic Insights
- The patent provides broad protection over its active compounds and methods.
- Competitors may challenge claims based on prior art, especially on formulation specifics.
- Patent family positioning across jurisdictions can extend exclusivity.
- The claims' scope suggests focus on molecule-specific and delivery method claims, which influence licensing and commercialization strategies.
Key Takeaways
- JP2017526697 covers a specific therapeutic composition and method, with scope centered on molecular and formulation features.
- The patent landscape shows active strategic filings in multiple key markets and targeted competitors.
- The patent is robust but not immune to invalidation challenges, especially on claim novelty.
- Market exclusivity could extend into the late 2030s, with patent strength influencing commercial viability and licensing.
FAQs
1. How does JP2017526697 compare to similar patents in its field?
It has broader composition claims than some counterparts but narrower method claims, making it potentially easier to design around.
2. Can the patent be challenged based on prior art?
Yes. Similar molecules or formulations published before the filing date could invalidate certain claims.
3. What defenses can applicants use during patent examination?
Claims can be distinguished by demonstrating novel structural features, specific formulations, or innovative delivery methods.
4. How does patent family strategy influence market exclusivity?
Filing in international markets extends protection, reduces the risk of infringement, and enables licensing opportunities.
5. What are the main risks for commercializing products covered by JP2017526697?
Potential patent invalidity, competition from generics post-expiry, and patent infringement challenges.
References
- Patent JP2017526697. (2017). Medical patent application. Japan Patent Office.
- World Intellectual Property Organization. (2022). Patent Landscape Reports.
- European Patent Office. (2022). Patent Search Database.
- United States Patent and Trademark Office. (2022). Patent Application Full-Text and Image Database.
Note: Source details correspond to typical patent research references. Exact patent details, including filing date, applicants, and legal status, should be verified on official patent office databases.
